<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04272736</url>
  </required_header>
  <id_info>
    <org_study_id>PKULite2018</org_study_id>
    <nct_id>NCT04272736</nct_id>
  </id_info>
  <brief_title>PKU Low Calorie Drink Study</brief_title>
  <official_title>Evaluating the Compliance, Acceptability, Safety and Tolerance of a Lower Calorie Protein Substitute for the Dietary Management of Phenylketonuria in Children and Adults - a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nutricia UK Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nutricia UK Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the compliance, acceptability, gastrointestinal (GI) tolerance and
      safety of a lower calorie amino acid based liquid protein substitute for patients with
      Phenylketonuria (PKU) or hyperphenylalaninemia (HPA).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compliance</measure>
    <time_frame>Daily for 31 days</time_frame>
    <description>Questionnaire on amounts offered and amounts actually consumed, compared to recommended amount. Amounts (values) are recorded</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acceptability: Tick-box questionnaire</measure>
    <time_frame>Recorded at baseline and end of intervetnion (day 31)</time_frame>
    <description>Tick-box questionnaire on overall liking and acceptability of product (ie dislike a lot, dislike moderately, neutral, like moderately, like a lot)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood phenylalanine and other amino acid levels</measure>
    <time_frame>Recorded at baselien and end of intervention (day 31)</time_frame>
    <description>Blood spot test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastro-intestinal tolerance</measure>
    <time_frame>recorded at baseline, beginning of intervention and end of intervention(12 out of 31 days in total)</time_frame>
    <description>Questionnaire detailing any GI symptoms, severity (none, mild, moderate, severe) and change from usual.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutrient intake</measure>
    <time_frame>Recorded at basleine and end of intervention (day 31)</time_frame>
    <description>24h dietary recall.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometry</measure>
    <time_frame>Recorded at baseline and end of intervention (day 31)</time_frame>
    <description>Measurements of height (m) and weight (kg) at baseline and end of study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Phenylketonurias</condition>
  <condition>Hyperphenylalaninaemia</condition>
  <arm_group>
    <arm_group_label>Low calorie protein substitute</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm designed, 3 day baseline, 28 day on the lower calorie amino acid based liquid protein substitute.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low calorie protein substitute</intervention_name>
    <description>The evaluated dietary supplement is a lower calorie amino acid based liquid protein substitute designed for patients with PKU.</description>
    <arm_group_label>Low calorie protein substitute</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  3 years of age or above

          -  Diagnosed with classical or variant type phenylketonuria (PKU), or
             hyperphenylalaninemia (HPA)

          -  Have been compliant in taking at least one amino acid-based, Phe-free protein
             substitute, providing at least 20g protein equivalent daily, for at least 1 month
             prior to study commencement

          -  Have a prescribed daily Phe allowance

          -  Written informed consent from patient, or from parent / carer if applicable

        Exclusion Criteria:

          -  Pregnant or lactating

          -  Requiring enteral tube or parenteral nutrition

          -  Major hepatic or renal dysfunction

          -  Participation in other studies within 1 month prior to entry to this study

          -  Allergy to any of the study product ingredients

          -  Investigator concern around the patient being underweight (e.g.: BMI lower than
             18.5kg/m2 for adults) and/or having an eating disorder

          -  Investigator concern around willingness/ability of patient or parent/carer to comply
             with protocol requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gary Hubbard, PhD</last_name>
    <phone>07738024720</phone>
    <email>gary.hubbard@nutricia.com</email>
  </overall_contact>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 29, 2018</study_first_submitted>
  <study_first_submitted_qc>February 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylketonurias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

